Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy

AIDS

Volumn 18, Issue 11, 2004, Pages 1503-1511

  Kantor, Rami ^a   Shafer, Robert W ^a   Follansbee, Stephen ^b   Taylor, Jonathan ^c   Shilane, David ^c   Hurley, Leo ^b   Nguyen, Dong Phuong ^b   Katzenstein, David ^a   Fessel, W Jeffrey ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Trials Unit   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Drug resistance; HIV; Resistance evolution

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; POL PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MUTATION RATE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STRUCTURAL GENE; TREATMENT FAILURE; VIREMIA; VIRUS LOAD; VIRUS MUTATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIRAL LOAD;

EID: 3843061223     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131358.29586.6b     Document Type: Article

References (32)

1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
2. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15:309-320.
3. Parkin NT, Deeks SC, Wrin MT, Yap J, Grant RM, Lee KH, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 2000; 14:2877-2887.
4. Harrigan PR, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, et al. Baseline HIV drug resistance profile predicts response to ritonavir- saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
5. Zolopa AR, Shafer RW, Warford A, Montoya JC, Hsu P, Katzenstein D, et al. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131:813-821.
6. Deeks SC, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179:1375-1381.
7. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
8. Cohen C, Kessler H, Hunt S, Sension M, Farthing C, Conant M, et al. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA 3001) [abstract 67]. Antivir Ther 2000; 5(Suppl 3):67.
9. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-F93.
10. Yeni PC, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-235.
11. Deeks SC, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus- infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-323.
12. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologice failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76:11104-11112.
13. Hawley-Foss N, Mbisa G, Lum JJ, Pilon AA, Angel JB, Garber G, et al. Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. Clin Infect Dis 2001; 33:344-348.
14. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, et al. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 2001; 39:1522-1529.
15. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:92-96.
16. Shafer RW, Jung DR, Betts BJ. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med 2000; 6:1290-1292.
17. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl Acids Res 2003; 31: 298-303.
18. Salminen MO, Carr JK, Burke DS, McCutchan FE. Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res Hum Retroviruses 1995; 11:1423-1425.
19. Halvas E, Aldrovandi GM, Balfe JP, Beck IA, Boltz V, Frenkel LM, et al. Updated, blinded, multicentre comparison of the sensitivity of different technologies to detect and quantify a minor drug-resistant HIV-1 variant. 12th International HIV Drug Resistance Workshop. Los Cabos, Mexico, June 2003 [abstract no. 92].
20. Izopet J, Cazabat M, Pasquier C, Sandres-Saune K, Bonnet E, Marchou B, et al. Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. Virology 2002; 302:393-404.
21. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039-1044.
22. Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol 2003; 77:5721-5730.
23. Fitzgibbon JE, Gaur S, Walsman SM, Janahi M, Whitley-Williams P, John JF, Jr. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens. AIDS Res Hum Retroviruses 2001; 17:1321-1328.
24. Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein T, Lundgren JD. The evolution of HIV in patients with insufficient viral suppression during HAART. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California, USA, September 2002 [abstract no. H-2058].
25. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003; 77: 4836-4847.
26. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
27. Birch C, Middleton T, Hales C, Cooper D, Law M, Crowe S, et al. Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing. J Acquir Immune Defic Syndr 2003; 32:57-61.
28. Hertogs K, Verbeist W, De Vroey V, De Hertogh P, Peeters F, Bloor S, et al. Continuing drug pressure did not alter drug resistance profiles between screening and baseline visits in the prospective trial VIRA 3001. Antivir Ther 2000; 5:126.
29. Maggiolo F, Callegaro A, Quinzan G, Arici C, Gregis G, Ripamonti D, et al. Evolution of HIV reverse transcriptase and protease mutations in patients on antiretroviral therapy. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California, USA, September 2002 [abstract no. H-2057].
30. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-766.
31. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165:105-110.
32. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-571.